

## **Pre X-Mas Symposium**

## iPS Based Cell Therapies- From Bench to Bedside

Hannover, Altes Rathaus / Old City Hall, December 3<sup>rd</sup> -4<sup>th</sup>, 2019

Tuesday, December 3 <sup>rd</sup> 08:30 Registration  09:00 Opening Robert Zweigerdt and Ulrich Martin  Session topic I: hPSC progeny production and the regulatory environment for cell therapies  Chairs: Sebastian Knöbel and Dirk Strunk  Key Note: Christine Mummery (NL) Intercellular dialogue in the heart modelled using differentiated hPSC  09:50 Paul Burridge (US) hPSC cardiomyocytes: Evolution of differentiation and application processes  10:15 Coffee break  10:45 Robert Zweigerdt (GER) Upscalling hPSC and progeny production including CMs, ECs and macrophages  11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience  Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  Received Therapies (UK) Peter Andrews (UK)	Tuesday	December 3 <sup>rd</sup>
Opening Robert Zweigerdt and Ulrich Martin		
Robert Zweigerdt and Ulrich Martin   Session topic I: hPSC progeny production and the regulatory environment for cell therapies		
Session topic I: hPSC progeny production and the regulatory environment for cell therapies Chairs: Sebastian Knöbel and Dirk Strunk  09:15 Key Note: Christine Mummery (NL) Intercellular dialogue in the heart modelled using differentiated hPSC  09:50 Paul Burridge (US) hPSC cardiomyocytes: Evolution of differentiation and application processes  10:15 Coffee break  10:45 Robert Zweigerdt (GER) Upscaling hPSC and progeny production including CMs, ECs and macrophages  11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:30 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michael Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	03.00	1
Chairs: Sebastian Knöbel and Dirk Strunk  09:15	Session to	
New Note: Christine Mummery (NL)   Intercellular dialogue in the heart modelled using differentiated hPSC		
Intercellular dialogue in the heart modelled using differentiated hPSC  09:50 Paul Burridge (US) hPSC cardiomyocytes: Evolution of differentiation and application processes  10:15 Coffee break  10:45 Robert Zweigerdt (GER) Upscaling hPSC and progeny production including CMs, ECs and macrophages  11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
Paul Burridge (US) hPSC cardiomyocytes: Evolution of differentiation and application processes		
hPSC cardiomyocytes: Evolution of differentiation and application processes  10:15 Coffee break  10:45 Robert Zweigerdt (GER)	09:50	
10:15 Coffee break  10:45 Robert Zweigerdt (GER)		
Upscaling hPSC and progeny production including CMs, ECs and macrophages  11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	10:15	
Upscaling hPSC and progeny production including CMs, ECs and macrophages  11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
11:10 Henrik Semb (DK) Pluripotent stem cells for cell therapy in T1D  11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	10:45	Robert Zweigerdt (GER)
Pluripotent stem cells for cell therapy in T1D  11:35		Upscaling hPSC and progeny production including CMs, ECs and macrophages
11:35 Gerald Schumann (GER) The current regulatory environment for iPS cell-based medicinal products  12:00 Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  Key note: Nissim Benvenisty Genomic variants in pluripotent stem	11:10	Henrik Semb (DK)
The current regulatory environment for iPS cell-based medicinal products  Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  Key note: Nissim Benvenisty Genomic variants in pluripotent stem		Pluripotent stem cells for cell therapy in T1D
Lunch with poster session Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova  Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	11:35	Gerald Schumann (GER)
Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER)		The current regulatory environment for iPS cell-based medicinal products
Session topic II: Sharing companies' perspective and experience Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30 Sebastian Knöbel, Miltenyi (GER)	12:00	Lunch with poster session
Chairs: Ina Gruh and Joseph Itskovitz-Eldor  13:30		Committee: Henning Kempf, Katharina Kinast, Ruth Olmer, Valeria Orlova
13:30 Sebastian Knöbel, Miltenyi (GER) Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
Making GMP-compliant media and reagents for cellular therapeutics  14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
14:00 Philipp Nold, DASGIP-Eppendorf (GER) and Serge Jooris, Ovizio (BEL) Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	13:30	
Innovations of Materials and Technologies for process development and monitoring of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
of cell therapeutics  14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	14:00	
14:30 Michal Izrael, Kadimastem (ISR) From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
From hPSCs Research to Cell Therapies for Neurodegenerative Disorders  Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  Key note: Nissim Benvenisty Genomic variants in pluripotent stem		· ·
14:55 Allan Karlsen, Novo Nordisk (DK) From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	14:30	
From hPSCs Research to Cell Therapies  15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	44.55	
15:20 Michael Harder, Corlife (GER) Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	14:55	
Cell-free allografts: the long journey of a therapeutic idea  15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	15.20	·
15:45 Coffee Break  Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty  Genomic variants in pluripotent stem	15.20	
Session topic III: (Genetic) Safety risks and ethics in cell therapies  Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	15.//5	
Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	15.45	Corree break
Chairs: Ivana Barbaric and Yoji Sato  16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem	Session to	onic III: (Genetic) Safety risks and ethics in cell theranies
16:15 Key note: Nissim Benvenisty Genomic variants in pluripotent stem		
Genomic variants in pluripotent stem		
	16:50	
The Origin, Mechanisms and Consequences of Acquired Genetic Variants in Human		, ,
Pluripotent Stem Cells		The Origin, Mechanisms and Consequences of Acquired Genetic Variants in Human















17:15	Ulrich Martin		
	Enrichment of Small Scale Genomic Variants during Reprogramming		
17:40	Dirk Strunk (AT)		
	Progress and risks in Mesenchymal Stromal Cell therapies		
18:05	Nils Hoppe		
	Stem Cells and Gene Editing: Legal and Ethical Issues		
18:30 Clos	18:30 Closing		
19:30 Eve	19:30 Evening Get-Together Gartensaal, Neues Rathaus		

Wedneso	lay, December 4 <sup>th</sup>
	opic IV: Current State in the Art of iPS cell based heart repair: large animal models
	cal translation
Chairs: C	hristine Mummery and Paul Burridge
09:30	Key Note: Yoji Sato (JP)
	Updates to Japan's regulation and/or quality issues of PSCs for cell therapies
10:05	Joost Sluijter (NL)
	Optimisation of cellular retention
10:30	Ina Gruh (GER)
	hPSC-derived cardiac aggregate transplantation in non-human primates
10:55	Coffee Break
11:30	Wolfram Zimmermann (GER)
	Translation of Engineered Heart Repair
11:55	Philippe Menasche (FR)
	hPSC-derived cardiomyocyte: clinical transplantation for heart repair
12:20	Poster session and lunch
	opic V: Current State in the Art of heart support or replacement and beyond:
	devices, human organ transplants
	hilippe Menasché and Wolfram Zimmermann
13:20	Key Note Johann Bauersachs and Axel Haverich (GER)
	- Cardiologist's view on the current clinical practice for treating heart failure
	- Surgeon's view on the current clinical practice for treating heart failure / Organ
	care system
14:10	Gregor Warnecke (GER)
	Clinical heart transplantation: Current State, Limitations and Perspectives
14:30	Coffee Break
	continued Chairs: Robert Zweigerdt and Ulrich Martin
15:00	Key Note Bruno Reichart (GER)
_	Xenotransplantation: pig hearts for human heart replacement <b>TBC</b>
15:35	Heiner Niemann (GER)
	Gene editing and porcine pluripotent stem cells: Novel tools for the production of
	multi-transgenic pigs for xenotransplantation
16:00	Samir Sarikouch (GER)
10.0=	Challenges in choosing heart failure patients for first-in-man iPS cell-therapies
16:25	Thomas Thum (GER)
40.50	Supportive strategies to foster cardiac hPS cell therapies
16:50	Meeting closing and poster prize winner announcement
	Robert Zweigerdt and Ulrich Martin











